Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

This news follows a recent Phase 3 trial where Keytruda®, another immunotherapy, failed to show similar benefits in the same setting. The success of Libtayo in this trial could represent a ...

This news follows a recent Phase 3 trial where Keytruda®, another immunotherapy, failed to show similar benefits in the same setting. The success of Libtayo in this trial could represent a significant ...